Tom Marjot
@tom-marjot.bsky.social
Liver doctor. NIHR Academic Clinical Lecturer at University of Oxford. Interested in #MASLD, #circadian rhythms, & #sleep. #EASL YI Taskforce.
Really nice to be hosting the BASL #MASLD SIG at Jesus College Oxford on 5th September
📢Attendance is FREE and registration is EASY. There are still a few spaces left.
🔗(tinyurl.com/4j8esadr)
Really great mix of speakers. AM = Basic/Translational science; PM = Clinical updates
📢Attendance is FREE and registration is EASY. There are still a few spaces left.
🔗(tinyurl.com/4j8esadr)
Really great mix of speakers. AM = Basic/Translational science; PM = Clinical updates
August 11, 2025 at 7:36 AM
Really nice to be hosting the BASL #MASLD SIG at Jesus College Oxford on 5th September
📢Attendance is FREE and registration is EASY. There are still a few spaces left.
🔗(tinyurl.com/4j8esadr)
Really great mix of speakers. AM = Basic/Translational science; PM = Clinical updates
📢Attendance is FREE and registration is EASY. There are still a few spaces left.
🔗(tinyurl.com/4j8esadr)
Really great mix of speakers. AM = Basic/Translational science; PM = Clinical updates
📢Great to write this review for Hep Comms with Matt Armstrong & @jonathanstinemd.bsky.social
💪We've covered everything you need to know about #Muscle & #MASLD
- Insulin resistance
- Sarcopenia
- Myosteatosis
- Impact of weight loss drugs
- Benefits of exercise
🔗 shorturl.at/aFO1Q
#LiverSky
💪We've covered everything you need to know about #Muscle & #MASLD
- Insulin resistance
- Sarcopenia
- Myosteatosis
- Impact of weight loss drugs
- Benefits of exercise
🔗 shorturl.at/aFO1Q
#LiverSky
May 25, 2025 at 12:02 PM
📢Great to write this review for Hep Comms with Matt Armstrong & @jonathanstinemd.bsky.social
💪We've covered everything you need to know about #Muscle & #MASLD
- Insulin resistance
- Sarcopenia
- Myosteatosis
- Impact of weight loss drugs
- Benefits of exercise
🔗 shorturl.at/aFO1Q
#LiverSky
💪We've covered everything you need to know about #Muscle & #MASLD
- Insulin resistance
- Sarcopenia
- Myosteatosis
- Impact of weight loss drugs
- Benefits of exercise
🔗 shorturl.at/aFO1Q
#LiverSky
Reposted by Tom Marjot
It was an absolute delight to contribute to this high-impact work with @tom-marjot.bsky.social and @mattarmstrong95.bsky.social in which we review all things #MASLD and #Muscle!
If you're looking for holiday weekend reading, look no further:
journals.lww.com/hepcomm/page...
@ebtapper.bsky.social
If you're looking for holiday weekend reading, look no further:
journals.lww.com/hepcomm/page...
@ebtapper.bsky.social
Skeletal muscle and MASLD: Mechanistic and clinical insights : Hepatology Communications
, which all converge on the liver to drive disease progression and adverse patient outcomes. This review explores the mechanistic links between skeletal muscle and MASLD, including the role of abnorma...
journals.lww.com
May 23, 2025 at 8:42 PM
It was an absolute delight to contribute to this high-impact work with @tom-marjot.bsky.social and @mattarmstrong95.bsky.social in which we review all things #MASLD and #Muscle!
If you're looking for holiday weekend reading, look no further:
journals.lww.com/hepcomm/page...
@ebtapper.bsky.social
If you're looking for holiday weekend reading, look no further:
journals.lww.com/hepcomm/page...
@ebtapper.bsky.social
Reposted by Tom Marjot
BS @easlnews.bsky.social Congress
Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social
& more!🔗https://tinyurl.com/4ky9r3x9
Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social
& more!🔗https://tinyurl.com/4ky9r3x9
April 15, 2025 at 3:55 PM
BS @easlnews.bsky.social Congress
Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social
& more!🔗https://tinyurl.com/4ky9r3x9
Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social
& more!🔗https://tinyurl.com/4ky9r3x9
Reposted by Tom Marjot
In these unprecedented dark times for American life science and medical research (no less well beyond biomedicine), my coping mechanism is to laser focus on the unremitting and remarkable daily advances, and the fervent hope these will not be slowed or interrupted.
March 6, 2025 at 9:34 PM
In these unprecedented dark times for American life science and medical research (no less well beyond biomedicine), my coping mechanism is to laser focus on the unremitting and remarkable daily advances, and the fervent hope these will not be slowed or interrupted.
Breakthroughs Beyond the Journal @jhepatology.bsky.social
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
March 17, 2025 at 1:53 PM
Breakthroughs Beyond the Journal @jhepatology.bsky.social
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
March 17, 2025 at 1:47 PM
Breakthroughs Beyond the Journal @jhepatology.bsky.social
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
🚨The liver is central to fructose-associated cancer
▶️Tumors cannot use fructose directly
▶️Liver converts to specific lipids (LPC)
▶️LPCs integrate into new cancer membranes
Can this explain link between MASLD & extra-hepatic cancer?
Reposted by Tom Marjot
Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit
Huge attendance and interest! 👏🏼
@tom-marjot.bsky.social @madsisraelsen.bsky.social
Huge attendance and interest! 👏🏼
@tom-marjot.bsky.social @madsisraelsen.bsky.social
January 24, 2025 at 1:43 PM
Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit
Huge attendance and interest! 👏🏼
@tom-marjot.bsky.social @madsisraelsen.bsky.social
Huge attendance and interest! 👏🏼
@tom-marjot.bsky.social @madsisraelsen.bsky.social
Reposted by Tom Marjot
2025 is the perfect year to take your career to the next level🚀
There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.
Apply by 20 January: easl.eu/leadership25
#LiverSky
There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.
Apply by 20 January: easl.eu/leadership25
#LiverSky
January 15, 2025 at 9:34 AM
2025 is the perfect year to take your career to the next level🚀
There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.
Apply by 20 January: easl.eu/leadership25
#LiverSky
There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.
Apply by 20 January: easl.eu/leadership25
#LiverSky
Reposted by Tom Marjot
January 6, 2025 at 9:13 PM
Reposted by Tom Marjot
Thoughtful piece from Marjot & Dhanda (@adhanda.bsky.social) in @natrevgastrohep.bsky.social: Alcohol-free drinks show promise for motivated individuals to reduce alcohol consumption but may pose relapse risks in others. Balance is key for clinical guidance. 🧪
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Alcohol-free and low-strength drinks: friend or foe? - Nature Reviews Gastroenterology & Hepatology
Consumption of no and low-alcohol (NoLo) beverages is now commonplace in modern society. However, the debate surrounding the relative risks and benefits of these products is nuanced and evolving, part...
www.nature.com
January 5, 2025 at 2:16 PM
Thoughtful piece from Marjot & Dhanda (@adhanda.bsky.social) in @natrevgastrohep.bsky.social: Alcohol-free drinks show promise for motivated individuals to reduce alcohol consumption but may pose relapse risks in others. Balance is key for clinical guidance. 🧪
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Tom Marjot
Do read my comment piece with @tom-marjot.bsky.social on NoLo alcohol 👇🏾
JAN ISSUE | COMMENT
Alcohol-free and low-strength drinks: friend or foe?
www.nature.com/articles/s41...
#Liversky #Gastrosky
Alcohol-free and low-strength drinks: friend or foe?
www.nature.com/articles/s41...
#Liversky #Gastrosky
January 3, 2025 at 9:46 PM
Do read my comment piece with @tom-marjot.bsky.social on NoLo alcohol 👇🏾
1: In 2025, look out for a new section in Journal of Hepatology: "Breakthroughs Beyond the Journal". Editorial-style analyses of pivotal liver research. #LiverSky
2: My comment on work from Cell Metabolism showing that MI drives #MASH. The interaction between these two conditions works BOTH ways👇
2: My comment on work from Cell Metabolism showing that MI drives #MASH. The interaction between these two conditions works BOTH ways👇
January 2, 2025 at 12:34 PM
Good to see you here @easlnews.bsky.social !
December 17, 2024 at 8:50 AM
Good to see you here @easlnews.bsky.social !
Reposted by Tom Marjot
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
December 6, 2024 at 8:24 PM
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Reposted by Tom Marjot
#LiverSky Come join in T-minus 26 mins for EASL Studio! #Sarcopenia #Exercise #Nutrition #Frailty #MASLD #LiverTransplant
💪 Excited to join as a panelist alongside #ShelleyKeating #FelicityWilliams #JenniferLai for Episode 8 of @EASLnews #EASLStudio2024 discussing #Sarcopenia in chronic liver disease on Wed Nov 27!
Don’t miss it! #LiverHealth #Hepatology #ClinicalPractice
easl.eu/easl-studio-...
Don’t miss it! #LiverHealth #Hepatology #ClinicalPractice
easl.eu/easl-studio-...
Sarcopenia: Converting research findings into clinical practice - Are we doing enough?
Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights ...
easl.eu
November 27, 2024 at 4:36 PM
#LiverSky Come join in T-minus 26 mins for EASL Studio! #Sarcopenia #Exercise #Nutrition #Frailty #MASLD #LiverTransplant
Reposted by Tom Marjot
Tumor seeding is a dreaded complication of biopsy for HCC. But how common is it?
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
November 27, 2024 at 2:05 PM
Tumor seeding is a dreaded complication of biopsy for HCC. But how common is it?
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
#LiverSky
Useful tip...
There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:
1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'
This will collate📌posts in a tab on your home screen + ⬆️ engagement.
Useful tip...
There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:
1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'
This will collate📌posts in a tab on your home screen + ⬆️ engagement.
November 26, 2024 at 12:11 PM
#LiverSky
Useful tip...
There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:
1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'
This will collate📌posts in a tab on your home screen + ⬆️ engagement.
Useful tip...
There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:
1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'
This will collate📌posts in a tab on your home screen + ⬆️ engagement.
Reposted by Tom Marjot
1/3 What happens when science and every day clinical practice comes together?
A 🧵
You get a packed room with not even a place to stand 👇🏼
Why?
I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings.
#TLM24
A 🧵
You get a packed room with not even a place to stand 👇🏼
Why?
I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings.
#TLM24
November 20, 2024 at 12:55 AM
1/3 What happens when science and every day clinical practice comes together?
A 🧵
You get a packed room with not even a place to stand 👇🏼
Why?
I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings.
#TLM24
A 🧵
You get a packed room with not even a place to stand 👇🏼
Why?
I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings.
#TLM24
Reposted by Tom Marjot
This artwork was published in the Journal of Immunology, published by @immunologyaai.bsky.social - which appears not to give a fork.
pubpeer.com/publications...
The Chinese government also did not see any problem.
www.science.org/content/arti...
#ThisImageIsFine
pubpeer.com/publications...
The Chinese government also did not see any problem.
www.science.org/content/arti...
#ThisImageIsFine
November 20, 2024 at 2:15 AM
This artwork was published in the Journal of Immunology, published by @immunologyaai.bsky.social - which appears not to give a fork.
pubpeer.com/publications...
The Chinese government also did not see any problem.
www.science.org/content/arti...
#ThisImageIsFine
pubpeer.com/publications...
The Chinese government also did not see any problem.
www.science.org/content/arti...
#ThisImageIsFine
Reposted by Tom Marjot
Reposted by Tom Marjot
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
November 15, 2024 at 3:17 PM
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky